Kenvue (NYSE:KVUE) Releases FY24 Earnings Guidance

Kenvue (NYSE:KVUE) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided EPS guidance of $1.10-$1.20 for the period, compared to the consensus EPS estimate of $1.14. The company issued revenue guidance of $15.59-$15.90 billion, compared to the consensus revenue estimate of $15.63 billion.

Analysts Set New Price Targets

A number of research analysts have commented on KVUE shares. Royal Bank of Canada lowered their target price on Kenvue from $25.00 to $24.00 and set an outperform rating on the stock in a research note on Friday, February 9th. Sanford C. Bernstein began coverage on Kenvue in a report on Thursday, April 11th. They issued an underperform rating and a $18.00 price objective on the stock. The Goldman Sachs Group assumed coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a neutral rating and a $20.00 target price for the company. JPMorgan Chase & Co. decreased their target price on shares of Kenvue from $25.00 to $24.00 and set an overweight rating for the company in a research report on Friday, February 9th. Finally, William Blair initiated coverage on shares of Kenvue in a report on Wednesday, April 3rd. They set a market perform rating on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of Hold and a consensus price target of $24.85.

Kenvue Stock Up 6.2 %

NYSE:KVUE traded up $1.17 during mid-day trading on Tuesday, hitting $20.05. 22,639,729 shares of the company’s stock traded hands, compared to its average volume of 16,955,277. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78. The firm has a 50 day moving average of $19.82 and a two-hundred day moving average of $20.11. Kenvue has a 12 month low of $17.82 and a 12 month high of $27.80.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. The company’s revenue was down 2.7% on a year-over-year basis. Equities analysts expect that Kenvue will post 1.15 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 3.99%. The ex-dividend date of this dividend is Tuesday, May 7th.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.